• Celonic Group leverages Merck’s Breez™ micro-bioreactor technology to optimize bioprocessing efficiency and scalability.
• This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies.
• Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in reducing the cost of goods per gram for biologics.

BASEL, Switzerland — Celonic Group, a Swiss-Based Quality contract development and manufacturing organization (CDMO), has announced that it is integrating Merck’s Breez™ micro-bioreactor platform into its process development. This addition will further enhance Celonic’s capabilities in monoclonal antibody (mAb) development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to large-scale manufacturing.

The Breez™ 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. By incorporating Breez™ into its process development, Celonic aims to accelerate upstream process optimization while reducing cost of goods per gram and increasing operational efficiency.

“This technology integration marks a significant milestone in our pursuit of innovative bioprocessing solutions,” said Samanta Cimitan Ph.D., CEO of Celonic Group. “By leveraging the Breez™ platform, we can enhance our ability to develop and manufacture biologics with the aim of increasing productivity, reducing the cost of goods per gram ultimately benefiting our clients and patients worldwide.”

Caption: Breez™ Micro-Bioreactor

About Celonic
Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in cell culture technologies, process development and manufacturing of recombinant proteins. Celonic’s roots trace back to 1982 as a spin-off of the Max Planck Institute in Germany. Today Celonic has a state-of-the-art Biologics Development and Innovation Center in Basel, Switzerland (Headquarters), and GMP manufacturing facilities in Heidelberg, Germany. This facility is equipped to handle complex biologics and bioprocessing technologies including fed-batch, N-1 perfusion and full perfusion production processes. At present, more than 500 highly qualified employees work at Celonic across the two locations.